A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence.
about
P1343
Profile of Susan Band HorwitzStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cellsUnderstanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulationsTubulin proteomics: towards breaking the code.A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryosPeloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.Altered TUBB3 expression contributes to the epothilone response of mitotic cells.Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents.Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules.Proteomics of cancer cell lines resistant to microtubule-stabilizing agents.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.An immunosurveillance mechanism controls cancer cell ploidy.Characterization of a human βV-tubulin antibody and expression of this isotype in normal and malignant human tissue.Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance.Taxol®: The First Microtubule Stabilizing Agent.The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.
P2860
Q23760720-70713097-00DB-4E3F-896E-45E6B743A920Q26781365-ED52B9FE-5BC1-4B42-8DD4-E86D281FEB13Q28478885-6DAE7D15-62D5-4587-BE13-5F7E553FBE1DQ28482107-B1B1A221-C1DB-40CC-AB3D-34EC48C9EFD4Q33687990-F639908A-A006-4665-9D44-9EAA2360A531Q35038184-34108C58-1BE0-4CC8-A0CF-5FDCC04BEA77Q35172172-B831F63F-B879-4EBB-87E4-C3407A820129Q36557893-AA9BA27E-1B4E-4261-AD59-172DED7DAC1EQ36772390-256EB2CA-1BB2-4F4E-8F22-E5A7DF94FB86Q36899935-6492D9CD-E158-4765-AA76-F0C3478844AAQ37625745-6ED55981-12CB-4DE8-A3E2-147B73DACDA6Q38087885-50B5BF21-CCC2-4131-BDD1-8C83FD935CE3Q39269872-547E82F5-517A-492B-86A3-C05DF7A4E1ADQ39295010-5C3B7A8C-5C39-44BE-8301-7B0799489A96Q39336478-81F17A09-D312-49C4-821C-99E35F1B9986Q41573963-5051D8C4-38C7-4078-8BA3-ECFB773427FAQ43137052-0072485D-048E-41A1-8C27-0D81EFEA812C
P2860
A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A highly epothilone B-resistan ...... n that confer drug dependence.
@en
type
label
A highly epothilone B-resistan ...... n that confer drug dependence.
@en
prefLabel
A highly epothilone B-resistan ...... n that confer drug dependence.
@en
P2093
P1476
A highly epothilone B-resistan ...... n that confer drug dependence.
@en
P2093
Chia-Ping Huang Yang
Eva Lippaine-Horvath
George A Orr
Gerhard Höfle
Pascal Verdier-Pinard
P304
P356
10.1158/1535-7163.MCT-05-0024
P4510
P577
2005-06-01T00:00:00Z